|By PR Newswire||
|April 25, 2014 08:01 AM EDT||
NEW YORK, April 25, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Perrigo Co. (NYSE: PRGO), GlaxoSmithKline plc (NYSE: GSK), Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Centene Corp. (NYSE: CNC) and Lorillard, Inc. (NYSE: LO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1616-100free.
Perrigo Co. Analyst Notes
On April 22, 2014, the shares of Perrigo Co. (Perrigo) gained 4.14%, closing the day at $151.55. During the session, the Company's shares opened at $147.61 and fluctuated in the range of $147.41 - $156.00. A total of 2.19 million shares of Perrigo were traded during the day, higher than its 30-day average trading volume of 0.99 million shares. Over the previous three trading sessions, the shares of the Company increased 5.74%, as compared to the NYSE Composite, which increased 0.89% during the same period. The full analyst notes on Perrigo are available to download free of charge at:
GlaxoSmithKline plc Analyst Notes
On April 22, 2014, GlaxoSmithKline plc (GSK) and Theravance, Inc. (Theravance) jointly announced the beginning of a Phase III efficacy and safety study of a combination treatment of the inhaled corticosteroid (ICS), fluticasone furoate and long-acting beta2 agonist (LABA), vilanterol (FF/VI). The study will be conducted to evaluate the contribution of the ICS component on lung function, in patients with Chronic Obstructive Pulmonary Disease (COPD). The Company informed that the positive results from this study will help support a potential filing of FF/VI for the treatment of patients with COPD in Japan. According to GSK, the study involves a 12 week, multicentre, randomised, double-blind, parallel-group study to evaluate the efficacy and safety of FF/VI 100/25mcg once daily compared with VI 25mcg once daily, administered through the Ellipta inhaler. The full analyst notes on GlaxoSmithKline are available to download free of charge at:
Intercept Pharmaceuticals, Inc. Analyst Notes
On April 12, 2014, Intercept Pharmaceuticals, Inc. (Intercept) announced the results from the Phase 3 POISE trial of obeticholic acid (OCA) for the treatment of primary biliary cirrhosis (PBC) to be presented in a late-breaker session at the International Liver Congress of the European Association for the Study of the Liver (EASL). Mark Pruzanski, M.D., CEO of Intercept, commented, "We believe OCA can fill a major gap in the treatment of PBC by providing an effective second-line therapy for the up to 50% of patients who do not achieve an adequate response with ursodiol, the current standard of care." Intercept plans to submit data from the Phase 3 POISE trial and the two Phase 2 trials of OCA for the treatment of PBC as part of a New Drug Application to the U.S. Food and Drug Administration and a Marketing Authorization Application to the European Medicines Agency. The full analyst notes on Intercept are available to download free of charge at:
Centene Corp. Analyst Notes
On April 22, 2014, Centene Corp. (Centene) announced its financial results for Q1 2014. The Company reported a 37.0% increase in revenues to $3.5 million, driven mainly by its expansions in Florida and Ohio, the additions of the California, New Hampshire and three Centurion contracts, the Company's participation in the Health Insurance Marketplaces, and the acquisitions of AcariaHealth and U.S. Medical Management. Net earnings for the quarter came in at $33.0 million, or $0.56 per diluted share, as compared to $23.0 million, or $0.42 per diluted share, in Q1 2013. Centene's adjusted diluted EPS of $0.79 was significantly higher than $0.46 as forecasted by analysts, on average, polled by Bloomberg. Looking ahead, the Company expects the full year 2014 diluted EPS to be in the range of $3.60 - $3.90. Centene's stock rallied 12.22% to close at $64.29 following the announcement. The full analyst notes on Centene are available to download free of charge at:
Lorillard, Inc. Analyst Notes
On April 14, 2014, Lorillard, Inc. (Lorillard) issued a press release to appreciate the legislation signed into law by Kentucky Gov. Steve Beshear, which will bar minors from buying electronic cigarettes. Murray S. Kessler, Chairman, President and CEO of Lorillard, said: "The Kentucky law demonstrates that it is possible to find common ground and sell responsibly to adults. It would be a mistake to let old divisions affect the development of electronic cigarettes, a new product with the potential to play a critical role in the national harm reduction discussion. Lorillard has actively supported age of purchase legislation in the states and encourages states that have not passed similar legislation to do so." The Company believes that it is also necessary to pass state laws prohibiting the sale of e-cigarettes to minors as many state do not disallow selling, furnishing and distributing electronic cigarettes to minors. The full analyst notes on Lorillard are available to download free of charge at:
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review